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Phthalates provide one of the most documented example evidencing how much we must be cautious when using
the traditional paradigm based on extrapolation of experimental data from rodent studies for human health risk
assessment of endocrine disruptors (EDs). Since foetal testis is known as one of the most sensitive targets of EDs,
phthalate risk assessment is routinely based on the capacity of such compounds to decrease testosterone
production by the testis or to impair masculinization in the rat during foetal life. In this paper, the well-established
inhibiting effects of phthalates of the foetal Leydig cells function in the rat are briefly reviewed. Then, data obtained
in humans and other species are carefully analysed. Already in January 2009, using the organotypic culture system
named Fetal Testis Assay (FeTA) that we developed, we reported that phthalates might not affect testosterone
production in human foetal testes. Several recent experimental studies using xenografts confirm the absence of
detectable anti-androgenic effect of phthalates in the human foetal testes. Epidemiological studies led to contradictory
results. Altogether, these findings suggest that phthalates effects on foetal Leydig cells are largely species-specific.
Consequently, the phthalate threshold doses that disturb foetal steroidogenesis in rat testes and that are presently
used to define the acceptable daily intake levels for human health protection must be questioned. This does not
mean that phthalates are safe because these compounds have many deleterious effects upon germ cell development
that may be common to the different studied species including human. More generally, the identification of common
molecular, cellular or/and phenotypic targets in rat and human testes should precede the choice of the toxicological
endpoint in rat to accurately assess the safety threshold of any ED in humans.
Keywords: Endocrine disruptors, Phthalates, Leydig cells, Masculinization, Human health, Risk assessment, Toxicity test,
Development, Reproduction, Foetus, Testis, TestosteroneRésumé
En toxicologie réglementaire, l’évaluation du risque sanitaire d’un perturbateur endocrinien (PE) est basée sur le
paradigme traditionnel qui consiste à extrapoler à l’espèce humaine les données obtenues chez l’animal. Les
phtalates fournissent un des exemples les mieux documentés montrant combien nous devons être prudents dans
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cette démarche. Le testicule fœtal est une cible privilégiée des PE et l’évaluation du risque sanitaire des phtalates a
été construite sur la capacité de ces produits à inhiber la production testiculaire de testostérone ou à réduire la
masculinisation pendant la vie fœtale chez le rat. Dans cet article, nous présentons brièvement les effets inhibiteurs
bien connus des phtalates sur les fonctions des cellules de Leydig fœtales chez le rat. Puis nous détaillons les
études effectuées chez l’homme et les autres espèces. Dès janvier 2009, en utilisant un système de culture
organotypique original que nous avions mis au point et nommé hFeTA pour human Fetal Testis Assay, nous avons
montré que les phtalates ne réduisent pas la production de testostérone par le testicule fœtal humain. En utilisant
des modèles de xénogreffes, plusieurs études ont confirmé récemment l’absence d’effet antiandrogénique
détectable des phtalates sur le testicule fœtal humain. Les études épidémiologiques ont conduits à des conclusions
contradictoires. En définitive, l’effet des phtalates sur les cellules de Leydig fœtales est largement dépendant de
l’espèce. En conséquence, on doit s’interroger sur le bien-fondé de l’utilisation actuelle de la dose minimale
induisant un déficit de la stéroïdogenèse dans le testicule fœtal de rat pour définir les normes réglementaires
d’exposition aux phtalates en santé humaine. Il faut noter que, bien que les phtalates semblent dépourvus d’effet
antiandrogénique sur le testicule fœtal humain, ils ne sont pas sans danger puiqu’ils altèrent le développement de
la lignée germinale chez l’Homme comme chez toutes les espèces étudiées. De façon plus générale, nous
préconisions que l’identification de cibles moléculaires, cellulaires, et/ou phénotypiques communes au rat et à
l’homme précéde le choix d’un paramètre critique utilisant le rat comme modèle en toxicologie réglementaire.
Mots-clés: Perturbateurs endocriniens, Phtalates, Cellules de Leydig, Masculinisation, Santé environnementale,
Évaluation du risque, Test de toxicité, Développement, Fœtus, Testicule, TestostéroneIntroduction
The risk of chemicals for human health is routinely
assessed by epidemiological and experimental studies.
The latters used a traditional risk assessment paradigm
based on the integration of both exposure assessment
and hazard characterization. Hazard characterization
is based on in vivo exposure of animals, particularly
rats and establishment of a dose response curve allowing
the identification of the lowest Non Observed Adverse
Effect Level (NOAEL). Then values obtained by this
methodology are extrapolated to human to define the
Tolerable Daily Intake (TDI). Regulatory Agencies are
aware of the difficulties due to the uncertainties linked to
extrapolation of experimental data from rodent studies to
human health assessment. Therefore, the NOAEL mea-
sured in rodent models is divided by a safety factor of 100
to define the regulatory acceptable dose for human health.
This safety factor is based on a factor of 10 to account for
the differences between rodents and humans multiplied
by an additional uncertainty factor of 10 to account for
inter-individual human differences in susceptibility.
However, new data show that this rule may be com-
pletely inappropriate for Endocrine Disruptor (ED) risk
assessment. By comparing the effects of various com-
pounds in rat, mouse and human foetal testes, we have
recently demonstrated that the extrapolation to human
species of data obtained in rodents is « illogical » in one
third of the analyses, whatever the security factor used,
because the effect observed in animals does not exist in
humans or vice versa [1]. Indeed, whereas fundamental
processes in biology, such as apoptosis, cell cycle or celldifferentiation, and their pathological disturbances (cancer)
are sustained by common basic mechanisms in various
species, hormonal regulations are often species-specific
in relation with evolution and the large variations in life
style. Differences are observed in many hormonal regu-
latory processes: biochemical nature of the hormone,
production level, control of the secretion, metabolism,
hormone receptors, signalling molecules… These differ-
ences are even more important in reproduction, the
most variable function from one species to another. As
an example linked with this paper, foetal Leydig cells are
stimulated by Chorionic Hormone (CG) as soon as they
differentiated in human species whereas there is no CG
physiologically active in the rat [2,3].
Many studies indicate that the incidence of male repro-
ductive function abnormalities in humans is increasing
over the years [4-7]. Although differences are observed ac-
cording to the country and even within regions of the
same country, human sperm count has been markedly
decreasing over the past four decades. A recent work
showed that sperm concentration in France has been de-
clining by 1.9% per year from 1996 to 2005 [8]. Moreover,
all studies show that the rate of testicular cancer has been
clearly increasing over the last decades. The prevalence
rates of cryptorchidism and hypospadias are also probably
increasing. According to the most common hypothesis,
named the «Testis Dysgenesis Syndrome», these abnor-
malities result from defaults in the development of the
testis during foetal life [9,10]. Furthermore, many epi-
demiological, clinical and experimental data suggest that
these male reproductive disorders are, at least in part, due
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ing more concentrated and widespread in our environ-
ment [5,6,9,11-20].
ED effects are often more severe when exposure oc-
curs during foetal life than in adulthood [21-26]. Foetal
testis thus appears to be a crucial ED target. Accord-
ingly, the tolerable dose intake of a given ED is often de-
rived from the measurement of its effects on the male
reproductive functions following foetal exposure. This is
the case for phthalates.
It is well established that some phthalates decrease tes-
tosterone production by foetal testes in the rat and this
anti-androgenic effect is routinely used for human health
risk assessment. The aim of this review is to question
the validity of this practice because recent data indicate
that phthalates do not have detectable anti-androgenic
effect in human foetal testes. After a rapid overview of
the effects of phthalates on foetal Leydig cell functions
and development in the rat, this review will detail data
obtained in human foetal testes and finally will extend
the analysis to other species.
Review
Human exposure to phthalates
Phthalates are phthalic acid esters the use of which
has been steadily increasing since 1930. Their world-
wide production grew from 1.8 to 4.3 million tons be-
tween 1970 and 2006. Phthalates are plasticisers that
are added to polymers and principally to PVC to make
them softer and more flexible. They are widely used in
many soft PVC products, including building and con-
struction materials, such as cabling, flooring, wall cover-
ing, profiles and roofs. They are components of medical
equipment, hoses, shower curtains, films and plastic gloves,
household furnishings, toys, car interiors, clothing, food
and beverage packaging, pharmaceutical products, etc.
Phthalates are also used as solvents for oil-soluble dyes,
insecticides, peroxides and other organic products. They
are added to paints and lacquers, adhesives and sealants,
cosmetics, lubricants, putty, perfumes, deodorants, sprays.
Di(2-ethylhexyl) phthalate (DEHP) was the most widely
used phthalate until recently. Now, it is progressively
replaced by di-iso-nonyl phtalate (DiNP) which is less
biologically active [21].
Phthalates are not covalently bound to the product
matrix and can leak out over time. For instance, they are
detected in domestic dust [27]. Dermal exposure may also
occur via clothes, cosmetics and medical equipment, such
as catheters and plastic pockets, for instance. Thus, humans
are constantly exposed to phthalates through the oral,
dermal and inhalation routes [28,29]. In the body,
phthalates are rapidly hydrolysed by esterases in the gut
and other tissues into monoesters that are the active
molecules [30,31]. For example, DEHP is metabolized toits monoester metabolite mono-(2-ethylhexyl) phthalate
(MEHP), and di-butyl phthalate (DBP) is converted into
mono-butyl phthalate (MBP).
The half-life of phthalates does not exceed 36 h in the
body. In humans, 75% of ingested DEHP is metabolized
and excreted in the urine within two days [32]. However,
phthalates are so widespread in the environment that
humans are constantly and largely exposed. According to
a study published in 2003, 12% of the German population
has a daily DEHP intake that exceeds the European
recommendations of 37 micrograms / kg body weight /
day [33]. Moreover, all biomonitoring studies highlight
the continuous co-exposure to different phthalates. For
instance, a North American study estimated that the
95th percentiles of daily exposure to DEHP, DBP, DEP
and butylbenzyl phthalate (BBzP) are 9.32, 2.68, 112.3
and 2.47 μg/kg/day, respectively [34]. The concentration of
phthalates in human biological fluids shows large individual
variations [35-42]. In pregnant women, the mean values in
urinary and amniotic fluid samples are 4.10−7 M for MBP
and 8.10−8 M for MEHP. The maximum MEHP concentra-
tions in urinary and amniotic fluid samples are 5.10−6 M
and 8.10−6 M, respectively.
Effect of phthalates in the rat
A very large body of works demonstrated that some
phthalates, those with a C3 to C7 lateral chain such as
DEHP, DBP, DiNP, BBzP, di-propyl phthalate (DprP),
dipentyl phthalate (DPeP), dihexyl phthalate (DHP),
dicyclohexyl phthalate (DCHP), butylbenzyl phthalate
(BBzP), and diisoheptyl phthalate (DIHepP), can reduce
the functions and development of foetal Leydig cells and
consequently impair masculinization in the rat.
Disturbances in foetal Leydig cell development and function
In all mammalian species, the first foetal Leydig cells
differentiate shortly after the differentiation of semin-
iferous cords [3,43-45]. In human testes, the functional
differentiation of Leydig cells begins at 6–7 weeks of
gestation (GW) and testosterone secretion is highest at
around 14 GW and then decreases [46,47]. In the rat,
the first functional Leydig cells differentiate at 15 day
post-conception (dpc) and foetal testis steroidogenic activ-
ity is highest at around 18.5 dpc (i.e., 3 days before birth)
[48]. Then, foetal Leydig cells progressively regress, at least
functionally, during the first two weeks of extrauterine life
[49-51]. It is important to note that the morphological,
functional and molecular characteristics of foetal Leydig
cells are different from those of adult Leydig cells, which
will differentiate at puberty. For instance, differently from
adult cells, foetal Leydig cells are not desensitized by high
concentrations of luteinizing hormone (LH)/human chori-
onic gonadotropin (hCG) [52,53], their initial differentiation
does not depend on LH/hCG [54,55] and their in vivo
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testicular regulations of Leydig cell functions differ be-
tween foetus and adult [3]. Moreover, aromatase, a key
enzyme in steroidogenesis, is strongly expressed by Sertoli
cells in adult testes, while it is essentially expressed by
Leydig cells in the foetus [57]. Similarly, FSH, which regu-
lates Leydig cells activity via paracrine factors produced by
Sertoli cells, inhibits testosterone production in the foetus
and stimulates its production in adult testes [58]. In the
rat, exposure to phthalates during the last week of preg-
nancy induces morphological, molecular and functional
alterations in foetal Leydig cells [16,43,59,60]. In re-
sponse to phthalates, foetal Leydig cells form clusters, de-
velop inside the seminiferous cords and change in size
(but not in number) [23,61-67]. Testis production of
testosterone is reduced in a dose-dependent manner
due to decreased expression of genes involved in chol-
esterol metabolism and transport (Star, HMG-CoA
synthase and Srb1) and in testosterone biosynthesis
(Cyp11a, 3beta-Hsd and Cyp17a1) [68-70]. Recently,
Sharpe et al. hypothesized that these changes are the
consequence of the prevention of Chicken ovalbumin
upstream promoter-transcription factor II (COUP-TFII)
down-regulation, a competitive inhibitor of steroidogenic
factor-1 (SF-1), which is required for the development and
maintenance of Leydig cell differentiated function [71].
Foetal Leydig cells also secrete insulin like-3 (INSL-3).
This hormone induces the transabdominal descent of
foetal testes from their initial mesonephrotic position to
the entrance of the inguinal duct, whereas the inguino-
scrotal descent is androgen-dependent [72]. Exposure to
some phthalates also reduces Insl-3 expression in the rat
foetal testis [73,74].
A comparison of the effect of various phthalates on
testosterone production by rat foetal testes showed
that DBP, DEHP, BzBP and diisobutylphtalate (DiBP)
are equipotent, dipentyl phthalate (DPP) is about three-fold
more potent and diethylphthalate (DEP) has no effect [75].
Masculinization defects in the rat
A reduction in foetal Leydig cell function variably impairs
masculinization in the rat and these effects are used as
endpoints for phthalate risk assessment.
In the male foetus, under the influence of androgens,
the Wolffian ducts differentiate into epididimydes, vas
deferens and seminal vesicles; the urogenital sinus gives
rise to prostate and bulbourethral glands, and scrotum
and penis are formed from the urogenital tubercle. In
the female foetus, in the absence of androgens, the basic
programme of differentiation is maintained: Wolffian
ducts regress, while urogenital sinus and tubercle form
the lower part of vagina, labia majora and labia minora.
Furthermore, the fallopian tubes, uterus and upper
part of the vagina spontaneously differentiate from theMüllerian ducts. Conversely in the male, Sertoli cells
produce Anti-Müllerian Hormone (AMH) that induces
Müllerian duct regression [76].
In the rat, the masculinization/defeminisation of in-
ternal and external genitalia begins at 18.5 dpc [77] and
therefore many studies on the anti-androgenic effects of
phthalates focused on the interval between 18.5 and
21.5 dpc. However, an important period for androgen-
dependent masculinization precedes this phenotypic
differentiation [78,79]. Indeed, a reduction of testosterone
synthesis or action between 15.5 and 18.5 dpc causes
masculinization defects, such as hypospadias, cryptorchid-
ism, incomplete development or agenesis of prostate and
seminal vesicles, reduction of the ano-genital distance
(AGD) and penis length. It was thus concluded that the
development of genitalia is programmed between 15.5 and
18.5 dpc, a period that was named the « masculinization
programming window ». A decrease in androgen produc-
tion after this period does not affect the ontogenesis of
male reproductive organs, but reduces their size and the
AGD. By analogy with the rat, if a « masculinization
programming window » exists in humans, it should be
between 7 and 14 GW.
Exposure to phthalates during foetal life causes many
masculinization defects in the rat [16,20,43,59,80-88].
Specifically, phthalates induce hypospadias, cryptorchidism,
gubernaculum alterations, defects in differentiation or
growth of epididymis, seminal vesicles, deferent ducts,
prostate, levator ani and bulbocavernosus muscles, Cowper’s
glands, and reduced AGD. Finally, whereas androgens
induce nipple regression at 12 days post-partum (dpp)
in the rat, phthalates induce nipples retention [89,90].
All these defects can be easily quantified and are the
usual endpoints to establish the NOAEL/lowest observed
adverse effect level (LOAEL) of phthalates. For instance, the
LOAEL for DEHP as been established to be 11 mg/kg/d
based on the reproductive organ malformations in adults
after exposure from 8.5 dpc to 17 dpp [91] and 10 mg/kg/d
based on AGD measurement at birth and on nipple reten-
tion at 12 dpp after exposure from 7.5 to 16.5 dpc [92].
Comparisons of the effect of various phthalates on
masculinization showed that DEHP=BBP >DINP>> >DEP,
DOTP, DMP [21] and DBP, BBP, DPeP, and DEHP >> >
DMP, DEP, and DOTP [93].
Effect of phthalates in humans
In contrast with the multitude of studies on phthalate
anti-androgenic effects in the rat, few data are available
on humans [13,16,43,94-96].
Epidemiological studies
In 2005, Swann et al. found a positive correlation be-
tween AGD (measured from the centre of the anus to
the anterior base of the penis) and penis volume, testis
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in the USA [37]. Therefore, they proposed to use AGD as
an easily accessible endpoint to evaluate the androgenic
activity of foetal and neonatal testes in humans,
similarly to what is done in the rat. They then inves-
tigated whether the AGD or the ano-scrotal distance
(ASD; measured between the centre of the anus and
the posterior basis of the scrotum) in 85 young boys aged
from 2 to 36 months was inversely correlated with the
concentration of various phthalate metabolites in maternal
urine samples collected during the last trimester of gesta-
tion. Three years later they strengthened their results by
increasing to 106 the number of mother-son pairs [97].
The main result of these two works is the existence of an
inverse correlation between AGD and the concentration
of MBP, monoisobutyl phthalate (MiBP) and several DEHP
metabolites in maternal urine samples. Conversely, AGD
was not associated with dibenzyl phtalate (DBzP) or di-n-
octyl phtalate (DNOP) metabolites. ASD was not associated
with any of these phthalate metabolites. Surprisingly both
AGD and ASD were associated with monoethyl phtalate
(MEP) concentration, a metabolite of DEP, which does not
have any anti-androgenic effect in the rat [21,75]. Finally,
the authors observed an inverse correlation between the
penis diameter (but not the length) and metabolites of
DEHP, but not of other phthalates.
Bustamante-Montes et al. [42] confirmed these results
[42]. They observed an inverse correlation between MEHP
concentration in maternal urinary samples during the last
trimester of pregnancy and AGD but not ASD, measured
24-48 h after birth, in 73 mother-son pairs in Mexico State.
Moreover, they found a significant inverse correlation be-
tween the cumulative MEHP, MBzP, MEP and MBP urinary
levels and AGD as well as penis width and stretched length.
However, MEHP was undetectable in the urine samples of
24 mothers, while mBzP, MEP and MBP urinary levels were
above detection level only in 8–10 mothers.
Choi et al. [98] searched for an increase of the concentra-
tions of DEHP, DBP, MEHP, MBP and phthalic acid in the
plasma or the urine of 40 children with hypospadias or in
the urine of their mother as compared with a control group
in Korea [98]. Only DEHP in the urine and phthalic acid in
the plasma were increased in the patient boys. Interestingly,
bisphenol A plasma concentration was sharply increased
(×7) in the plasma of the patient group.
Similarly, Suzuki et al. [41] did not find any correl-
ation between AGD at birth and the concentrations of
DBP, DMP, DEP, DBzP and DEHP (MEHP and MEOHP)
metabolites in maternal urine samples collected between
the 9th and the 40th GW in 111 Japanese mother-son
pairs [41]. Only AGD, but not ASD, correlation with
MEHP concentrations was almost significant.
Lastly, Huang et al. [40] did not detect any association
between ASD at birth and MEHP or MBP concentrationin maternal urine samples collected at 16–20 GW in 33
mother-son pairs in Taiwan [40].
The difficulty to establish an association between ex-
posure to phthalates and androgenic deficiency could
be explained by the fact that maternal urine samples
are most often collected during the third trimester of
pregnancy (i.e., after the masculinization programming
window, between 7 and 14 GW). Significant higher risk
of hypospadias was found in boys whose mothers were
professionally exposed to phthalates (and thus particu-
larly during the first trimester of pregnancy), including
hairdressers, beauty therapists, research chemists, line
operators, pharmaceutical operators, electrical assemblers,
factory assistants, compared to boys whose mothers were
not exposed to phthalates at work [99]. However, people
who are professionally exposed to phthalates are also ex-
posed to many other confounding anti-androgenic factors.
Another difficulty is linked to the fact that maternal
urine levels of a compound or its metabolites may not
be indicative of a direct effect of these compounds on the
testis in the fetal compartment. This is particularly the
case for phtalathes since phthalates are rapidly hydrolyzed
by esterases in the gut and other tissues to monoesters,
which are the active molecules [30].
The strength of these works could be also limited by
the fact that phthalate exposure was always evaluated in
a single sample. Nevertheless, according to Teitelbaum
et al. [100], a single urine sample is often representative
of exposure over a 6-month period to warrant its use as
an exposure estimate in epidemiological studies [100].
Moreover, phthalates may exert phenotypical anti-
androgenic effects by acting on targets different from
the fetal testis as suggested by some epidemiological
studies that reported an effect also in the female foetuses.
Huang et al. [40] observed an inverse correlation between
the distance from the anus to the posterior convergence
of the fourchette in female new-borns and the concentra-
tion of MBP in amniotic fluid samples [40]. Furthermore,
Sathyanarayana et al. [101] reported the association be-
tween lower circulating testosterone levels and increased
DEHP and DBP exposure in women carrying female foe-
tuses during the second and the third trimester of preg-
nancy [101]. This association was found also in women
carrying male foetuses, but only for DEHP and not DBP.
The main limit of these epidemiological studies is the
presence of confounding factors. Specifically, exposure to
phthalates is often associated with exposure also to bisphe-
nol A (BPA), a powerful inhibitor of human foetal Leydig
cell activity [102]. High levels of plasma BPA have been
shown to be strongly associated with hypospadias in
Korean boys [98]. The bias resulting from confounding
factors could explain the inverse association between
AGD and exposure to MEP, a compound without anti-









Figure 1 The Foetal Testis Assay (FeTA) as a usefull tool to
measure the effects of Endocrine Disruptors. Foetal Testis Assay
(FeTA) was developed by our laboratory for rat, mouse and human
species [47,103-108,126]. Human, rat or mouse foetal testes are cut
in small pieces of a volume of about 0.2 mm3/each piece, at all
developmental stages and in all studied species. One to four pieces
are randomly placed on Millicell-CM Biopore membranes (pore size
0.4 μm, Millipore, Billerica, MA) floating on 320 μL culture medium in
tissue culture dishes. One to eight wells per testis are thus prepared,
depending on the species and the age at explantation. The culture
medium is phenol red-free Dulbecco modified Eagle medium/Ham
F12 (1:1) without addition of any biological factor or hormone.
Testes are cultured at 37°C in a humidified atmosphere containing
95% air/5% CO2 for three or four days. Medium is completely
changed every 24 h. The androgenic and masculinizing activities of
cultured testes are evaluated based on the amount of testosterone
that is secreted daily by foetal Leydig cells of each testis, on the total
number of foetal Leydig cells per testis, or the expression of Leydig
cell markers (steroidogenic enzymes or actors, INSL3, LH Receptors).
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confirming or infirming the existence of an association
between phthalate exposure and reduced androgenic
activity of foetal testes in humans.
Experimental studies
Three independent research groups (headed by K.
Boekelheide, R. Habert and R. Sharpe) failed to find
any anti-androgenic effect of phthalates in foetal human
testes using experimental in vitro and in vivo models.
Studies using in vitro models Historically, the first
report on the absence of detection of phthalate anti-
androgenic effects in human testes was by the group
directed by Richard Sharpe using an organotypic culture
model. However, they did not conclude that humans
are not responsive to phthalate anti-androgenic effects
and attributed this observation to the inability of their
in vitro system to detect such an effect [63]. Human
foetal testes at 15–19 GW were cut in small pieces and
the same number of pieces was deposited on filters
immersed in culture medium with or without 10−3 M MBP
for 24 hours. MBP did not change basal, hCG-stimulated
and 22R-hydroxycholestorol-stimulated testosterone secre-
tion. As a positive control the authors used rat testes from
19.5 dpc foetuses (a developmental stage comparable with
15–19 GW human foetuses because testis testosterone pro-
duction is highest at 18.5 dpc in the rat and at 14 GW in
humans) [3]. They confirmed that oral gavage in pregnant
rats with 500 mg/kg/day DBP at 19.5 dpc reduced testoster-
one production by foetal testes in vivo. Conversely, in their
in vitro system, 10−3 M MBP did not reduce basal and 22R-
hydroxycholesterol-stimulated testosterone secretion, but
only decreased hCG-stimulated secretion in cultured rat
testes. The authors concluded that their in vitro approach
was not suitable for toxicological purposes and that their
observation that phthalates did not alter testosterone pro-
duction in humans was explained by the limitations of the
used in vitro method.
Using an organotypic culture system that we developed
and named Foetal Testis Assay (FeTA) [16,47,103-108]
(Figure 1), we affirmed for the first time in January 2009
that phthalates do not reduce testosterone production (and
INSL3 expression) in human foetal testes [109] (Figure 2).
We validated this culture system as a powerful in vitro
model to test the effects of EDs [1,103,110].
Testis explants were deposited on an insert at the air-
medium interface to allow the survival and development
of all testis cell types. Human foetal testes were issued from
legal abortions performed between 7–12 GW, a period
comparable to 15.5-18 dpc in the rat and corresponding to
the « Masculinization Programming Window ». All pieces
from one testis were cultured with MEHP concentrations
ranging from 10−6 M to 10−4 M for 3 days. All piecesfrom the other testis were cultured without MEHP and
served as control. Using this system, we showed that, at all
concentrations tested, MEHP does not change the daily
basal and LH-stimulated testosterone secretion or the
expression of genes involved in testosterone biosynthesis
(StAR, CYP11A and CYP17A1). Similarly, also INSL3 ex-
pression was unaffected [103].
Many positive and negative controls validated these
conclusions:
– In these testis explants, 10−4 M MEHP reduced by














































Figure 2 Comparison of the effects of one phthalate as a function of the species. Testes at similar stage of development i.e. from 7–11 GW
human foetuses, 14.5 day-old rat fetuses, or 13.5 day-old mouse foetuses were cultured using the FeTA system described in Figure 1. For each
foetus, one testis was cultured in the absence (control) and the other one in the presence of MEHP at concentrations ranging from 10−6 to 2×10−4 M
for 3 days. The daily testosterone secretion was measured by radioimmunoassay. Only values on the third day are presented here but results are
similar for the other two days of treatment. Values (means ± SEM) are expressed as the percentage of the secretion of the treated testis compared with
that of the control testis. MEHP had negative, positive or no effect with rat, mouse or human fetal testes respectively. Bisphenol A (BPA) at various
concentrations was used as positive control for human fetal testes *p < 0.05, **p < 0.01, ***p < 0.001 compared with control testis using the Wilcoxon’s
non-parametric paired test. From [1,102,109,121].
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significantly increased by exposure to MEHP doses
as low as 10−5 M [110]. Furthermore, MEHP in-
creased the size of lipid droplets and the expression
of LXR alpha, of downstream genes, such as
SREBP1, SREBP2, and of genes involved in choles-
terol and lipid biosynthesis [111].
– Using the FeTA system we showed that human foetal
Leydig cells can respond to other EDs as indicated by
the finding that exposure to 10−8 M BPA reduces tes-
tosterone production and INSL3 expression [102].
– In the FeTA system, exposure to 10−4 and 10−5 M
MEHP reduced the basal testosterone production
of rat testes explanted at 14.5 dpc and cultured
for three days [1]. Importantly, 14.5 to 17.5 dpc is
a developmental period comparable with 7–12
GW in humans. The finding by Hallmark et al.
[63] that MBP did not have a negative effect on
basal testosterone production in foetal rat testes
in vitro can be explained by the protocol used by
these authors who deposited pieces of testes from
different animals in the same well [63], whereas in
the FeTA system we compare all pieces of one
testis to all pieces of the other testis from the
same foetus. Moreover, rat foetal testes are less
susceptible to phthalates at 19.5 dpc (stage used by
Hallmark et al.) than at 14.5 dpc. Indeed, addition of
10−3 M MBP reduced basal secretion of testosterone
by 41% in 19.5 dpc rat testes and by 60% in 14.5 dpctestes cultured in the FeTA system for two days (per-
sonal data).
– Other EDs such as diethylstylbestrol reduced testos-
terone production by the fetal testis in rodents but
not in human [11,102,112].
In conclusion, although our in vitro approach displays
intrinsic limits (absence of vascularization, cell survival
limited to a few days) it allows the sensitive, direct, rapid,
not labour-intensive and relatively cheap evaluation of the
toxic effects of a given compound on foetal testis develop-
ment and functions [1]. Using this method, we never de-
tected any anti-androgenic effect of phthalates in human
foetal testes, whereas we always did in rat foetal testes.
Studies using xenograft models Three recent studies
from the Sharpe’s and Boekelheide’s laboratories described
in vivo models in which human testes were xenografted
in rodents.
Richard Sharpe’s group was the first to develop this ap-
proach [113]. Human foetal testes at 14–20 GW were cut
in small pieces that were grafted under the skin of castrated
CD1 nude mice. In this model, the different testis cell types
can survive and develop for six weeks. Specifically, foetal
Leydig cell activity (based on the host testosterone concen-
tration or seminal vesicle size) was maintained when the
host mice were treated with hCG to mimic normal preg-
nancy. To evaluate the anti-androgenic effect of phthalates,
human foetal testes were xenografted in castrated male
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500 mg/kg/day of DBP or MBP for 4–21 days [114].
Serum testosterone and seminal vesicle weight did not
differ in vehicle-, MBP- and DBP-treated host mice.
Conversely, in mice xenografted with 17.5 dpc rat foetal
testes (positive control), DBP treatment significantly
reduced seminal vesicle weight in the host as well as
Cyp11a1 and StAR expression in the graft.
Kim Boekelheide’s group used another approach [115].
Human foetal testes at 10–24 GW were cut in small
pieces and grafted in the renal capsule of adult nude
male rats that were then force-fed with 0, 100, 250 or
500 mg DBP/kg/day for two or three days. DBP treat-
ment did not change the expression of INSL3 and key
genes in cholesterol metabolism and steroidogenesis
(SCARB1, STAR, CYP11A1 and CYP17A1) in the grafts. As
internal positive control, the authors reported that the num-
ber of multinucleated gonocytes in the grafts was increased
in response to all DBP doses used. However, they did not
observe a reduction in gonocyte density, whereas phthalates
decreased gonocyte number by increasing their apoptosis in
the FeTA system [109,110]. As another positive control, the
authors grafted 16.5 dpc foetal rat testes in nude rats.
Gavage of the host with 500 mg DBP/kg/day for two
days reduced by half the ability of the graft to produce
testosterone and to express Cyp17a1, Scarb1 and Insl3.
A recent paper from this group confirmed these data
[116]. Testis pieces from human foetuses at 10–24 GW
were grafted in the renal subcapsular space of castrated
adult nude male mice. Animals were then treated with
hCG and gavaged with vehicle or 500 mg DBP/kg/day or
75 mg/kg/day of abiraterone acetate (a CYP17A1, inhibitor).
The plasma testosterone concentration of the mice was
unaffected by DBP, whereas it was dramatically reduced
by abiraterone acetate. Furthermore, DBP treatment did
not affect the host accessory sex organ weight, whereas
the weight of seminal vesicles and levator ani and bul-
bocavernosus muscle complex was reduced in hosts
treated with abiraterone acetate.
In conclusion, although the xenograft model displays
intrinsic limits (variability in the survival of grafted pieces,
host compensatory reactions, differences between the me-
tabolism in the host and in human…), this approach allows
the long-term evaluation of the toxic effects of one chem-
ical compound on foetal testis development and functions.
The three mentioned papers used different methods
and endpoints, but they all confirmed and extended
the results obtained with the FeTA model that phtha-
lates are not anti-androgenic in human foetal testes in
experimental settings.
Effect of phthalates in other species
In stark contrast with the many works on phthalate effects
in the rat, very few studies focused on other mammals.Effect of phthalates in the rabbit
In the only available study [22], 400 mg/kg/day of DBP
was administered orally to pregnant rabbits from 15 dpc
(i.e., just after testis differentiation) to 29 dpc (i.e., three days
before birth). DBP treatment decreased serum testosterone
levels in male offspring (n = 17) at 6 weeks post-partum,
but not thereafter; the weight of testes and accessory sex
glands was reduced at 12 weeks post-partum. Furthermore,
one rabbit (1/17) had hypospadias, hypoplastic prostate and
cryptorchid testes with carcinoma in situ-like cells. After
reaching adulthood, these rabbits showed a qualitative and
quantitative decrease in sperm.
This study suggests that phthalates have anti-androgenic
effects in male rabbit foetuses. However, the incidence
of reproductive tract malformations following exposure
to DBP is lower in rabbits than in rats [43].
Effect of phthalates in the mouse
The first study was performed by Boekelheide’s group
[117]. Gavage of pregnant mice with DBP (1500 mg/kg/day),
MBP (1000 mg/kg/day) or MEHP (1000 mg/kg/day) from
14.5 to 16.5 dpc or from 15.5 to 17.5 dpc did not change
foetal testis testosterone concentration and Scarb1 and
Cyp11a1 mRNA expression at 17.5 dpc. Importantly,
like in the rat, these treatments caused an increase in
multinucleate gonocytes. Gavage with an unique dose of
DBP (500 mg/kg) at 18.5 dpc did not reduce the expres-
sion of key genes involved in cholesterol transport and
metabolism (Scarb1, Dhcr7, Star) and in testosterone
biosynthesis (Cyp11a1, Cyp17a1) measured 4–8 h after
gavage. These genes were all down-regulated in rat foe-
tuses treated using a similar protocol [68]. The authors
concluded that, differently from the rat, phthalates do not
have an anti-androgenic effect in mouse foetal testes.
On the other hand, Liu et al. [118] observed a dose-
dependent increase in hypospadias in new-born mice from
pregnant animals that received 100, 200 or 500 mg/kg/day
of DEHP from 12.5 dpc (i.e., when the first foetal Leydig
cells differentiate) to 17.5 dpc (i.e., two days before birth)
[118]. AGD was also decreased in animals exposed to the
highest dose.
Do et al. [119] gave 0, 0.0005, 0.001, 0.005, 0.5, 50 or
500 mg/kg/day of DEHP to pregnant mice from 9 to
18.5 dpc [119]. With the exception of the 500 mg/kg/day
dose that did not have any effect, plasma and testis tes-
tosterone levels and AGD measured 2–4 hours after the
last gavage were increased in male foetuses according to
an inversed U-shaped dose–response curve in agreement
with the results by Gaido et al. [117].
In another study, 100, 200 or 500 mg/kg/day DEHP given
to mice from 12.5 dpc to 3 dpp decreased testis Insl3 expres-
sion measured at 5 dpp in a dose-dependent manner [120].
Heger et al. [115] analyzed mouse testes from 15.5 dpc
mouse implanted into adult male immunodeficient host
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500 mg/kg/day DBP by oral gavage [115]. Quantitative
RT-PCR analysis did not reveal any change of the expres-
sion of the Leydig cell–specific genes Ex vivo testicular incu-
bation showed slight DBP-induced increase in testosterone
production. On the opposite, all these parameters were
decreased by DBP in 16.5 dpc rat grafted fetal testes.
Finally, an in vitro study highlighted the complexity of
the response to phthalates in the mouse and tried to
reconcile the contradictory data described above [121].
Mouse foetal testes were cultured using the FeTA sys-
tem in the presence or not of 2.10−4 M MEHP for three
days. MEHP increased basal testosterone production
by testes explanted at 13.5 or 18.5 dpc, but decreased
LH-stimulated testosterone secretion by testes explanted
at 18.5 dpc. As LH secretion physiologically appears in
late foetal life, these in vitro data explain why phthalates
have antiandrogenic effects in the mouse only during late
foetal or neonatal life, while they do not have any effect or
show positive effects before late foetal life in the in vivo
experiments described above.
Effect of phthalates in the marmoset
The group headed by Richard Sharpe tested the effects
of phthalates also in marmosets. Indeed, this non-human
primate (Callithrix jacchus) could be a better model for
assessing the effects on humans than rodents [122]. Preg-
nant female marmosets received 500 mg/kg/day of MBP
from the 7th to 15th week of gestation and male offspring
were studied at birth. This period overlaps with the human
«masculinization programming window» because the for-
mation of the gonad occurs during week 6 and the duration
of pregnancy is of 21 weeks in this species [123]. MBP did
not affect gross testicular morphology, reproductive tractTable 1 Effect of DEHP/MEHP and DBP/MBP on fetal Leydig c



















Rabbit Early + late stages
Marmoset Early + late stagesdevelopment or testosterone levels at birth. Conversely, a
similar treatment in rats causes 17% hypospadias and 70%
cryptorchidism [64]. Differently from what observed in hu-
man and rat testes, neither the number nor the differenti-
ation of Sertoli cells and gonocytes was affected by MBP.
Multinucleated gonocytes were not observed in both con-
trol and MBP-treated new-born marmosets, but abnor-
mally aggregated gonocytes were detected in 33% of treated
new-borns, as previously reported in the rat [124].
Although this study did not include positive controls
and did not demonstrate that with this protocol DBP/MBP
could reach the foetal testes, it suggests that Leydig cells are
not affected by phthalates during foetal life in marmosets.
Table 1 schematically summarizes the differences ob-
served in the various studied mammals.
Conclusion
The toxicological reference values of various phthalates
are mostly based on their anti-androgenic effects in the
rat foetus; however, more and more studies show suggest
that these effects do not exist in humans. Similarly,
phthalates do not reduce foetal Leydig cell activity in
the mouse during the beginning of testis development
and in foetal marmoset, whereas they might have a
weak anti-androgenic effect in rabbits. This suggests
that phthalates suppress foetal Leydig cell steroidogen-
esis specifically in the rat.
The explanation for this species difference is not yet
established. However, Veeramachaneni and Klinefelter re-
cently observed that, DEHP exposure induced an increase
in circulating oestradiol in the rat and they supposed that
aromatase is one of the primary targets of phthalates [96].
Since oestradiol reduces testosterone production by the rat
fetal testis [112] but not by the human fetal testis duringell functions in human and various species
Observation References
nce for an association between a reduction of
masculinization and phthalates exposure
37, 42, 97, 99
evidence for an association between a reduction
f masculinization and phthalates exposure
41, 98, 101
any association between masculinization and
phhtalates exposure
40
No effect of phthalates 109, 110
No effect of phthalates 63, 114-116
Strong negative effect of phthalates
1, 23, 25, 61, 63–70,
75, 80–88, 90-93
Negative effect of phthalates 63, 89
Positive effect of phthalates 115, 118, 119, 121
Negative or no effect of phthalates 117, 121
Negative effect of phthalates 22
No effect of phthalates 122
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could explain the species difference concerning phthalate
anti-androgenic effects. The species difference in the
oestrogen anti-androgenic effect has been explained as
follow : estradiol reduced fetal testicular testosterone
production via ESR1 [11,102,126] and ESR1 expression
(mRNA and protein) is not detected in human fetal
testes [127].
This review focused only on phthalate exposure during
foetal life, because this period is particularly sensitive to
endocrine disruption and, thus, intrauterine exposure to
phthalates is normally used to evaluate phthalate hazards.
The critical susceptibility to EDs extends to neonatal life,
but no experimental data on the adverse effects of phtha-
lates in humans during this developmental period are
presently available. An anti-androgenic effect of phthalates
during this period cannot be excluded because foetal
and neonatal Leydig cells are different in human [3] and
exposure to DBP reduces plasma testosterone levels in
marmoset neonates, but not in foetuses [63].
While phthalate effects on Leydig cell development
and function are highly variable from one species to an-
other, their adverse effect on the seminiferous compartment
has been reported in foetuses of all studied species. How-
ever, it is difficult to perform a precise inter-species com-
parison in this case because the number of studies is very
limited. Furthermore the analysed endpoints differ from
one study to another. It is clearly established that phthalates
increase the development of multinucleated gonocytes in
the rat during late foetal life [23,64,124,128,129] and in the
mouse [117,130]. However, this was not observed in
marmosets [122], and in humans phthalate-induced
multinucleated gonocytes were not detected during the
first trimester of gestation [109] but only later, starting
from the second trimester [115,116]. Gonocyte apoptosis
may be another phthalate-responsive endpoint common to
different species because it was observed in vitro [131] and
in vivo [129] in the rat, and in vitro in mouse [121] and hu-
man foetal testes [103,110]. Unfortunately, this endpoint
has not been studied in xenografted human foetal testes. It
is not clear whether phthalate-induced disturbances in
gonocyte development result from a direct effect on this
cell type or whether they are mediated by Sertoli cells. In-
deed, Sertoli cell proliferation and/or gene expression are
altered by phthalates both in rat and human foetuses
[103,132,133]. In conclusion, as gonocytes and Sertoli cells
are common targets of phthalates in different species, in-
cluding humans, efforts should be made to define a set of
genes the expression of which is changed by phthalates
both in rat and human testes in order to establish new end-
points for human risk assessment.
More generally, the identification of common molecu-
lar, cellular or/and phenotypic targets in both rat and
human models should precede the choice of a toxicologicalendpoint in the rat to accurately assess the safety threshold
of any ED in humans.
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